ValorQ4, 24Q4, 25TTMGastos comerciales, generales y administrativos———Investigación y desarrollo———Beneficio operativo———Total de ingresos no operativos———Gastos por intereses, netos de intereses capitalizados———Ingresos no operativos, una vez deducidos los gastos por intereses———Ingresos/gastos extraordinarios———Beneficio antes de impuestos———Participación en los beneficios———Impuestos———Participación minoritaria———Otros ingresos/gastos después de impuestos———Beneficio neto antes de actividades interrumpidas———Operaciones suspendidas———Beneficio neto———Ajuste por dilución———Dividendos de las acciones preferentes———Beneficio neto diluido atribuible a los accionistas———Beneficio básico por acción———Beneficio por acción diluido———Número medio de acciones ordinarias———Acciones diluidas———EBITDA———EBIT———Costo de los ingresos———Otros costes de producción———Amortización y depreciación (flujo de caja)———
BioNTech SE - American Depositary Shares
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic.